BPS 2012 Proceedings

Boulder Peptide Symposium, 2012

Peptide Showcase

Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.

Jan Johansson

CEO
ARTERY Therapeutics, Inc.

Artpep2 is a ApoA-I mimetic that Reduces Atherosclerosis

Dinesh Patel

CEO & President
Protagonist Therapeutics Inc

Disulfide rich peptides as novel therapeutic agents

Craig Beattie

Chief Science Officer
CDG Therapeutics Inc.

Cell Penetrating Peptides as Chemotherapeutic Agents

Pascal Deschatelets

COO
Apellis Pharmaceuticals, Inc.

Inhibiting the complement system to modifying chronic inflammatory diseases.

Ken Hoober

CSO
Susavion Biosciences, Inc.

An Innovative Approach to Immunotherapy

Justin Romanowski

Manager, Business Analytics
Unigene Laboratories, Inc

The Solution to Oral Peptide Delivery

John Kinzell

CEO
Xeris Pharma

A New Paradigm for Injection….

Joe Audie

CSO
CMD Bioscience LLC

CMDInventus: a computational platform to enable the discovery of novel peptide therapeutics.

Metabolic Disease

Preclinical and Clinical Developments of Peptides in Metabolic Disease

Christina Rondinone

VP Research and Development
Medimmune

Peptides: New therapies for metabolic diseases?

Jahoon Kang

Unknown
Hanmi

Pharmacokinetic and Pharmacodynamic Effects of a Single Dose of the Long-Acting GLP-1R Agonist HM112

Andrew Young

Head Endocrine Biology
Glaxo Smith Kline

Attributes Necessary for a Commercially Successful Metabolic Peptide

Wolfgang Glaesner

Chief Scientific Officer,AME
Eli Lilly and Co

Glp-1 Agonist Based Therapies: Engineering Considerations And Development Of Dulaglutide, A GLP1-Fc

Frank Tagliaferri

Vice President R&D
4P Therapeutics

Recent Advances in the Transdermal Delivery of Biopharmaceutics

Jean Lachowicz

Chief Scientific Officer
Angiochem

Peptide Drug Conjugates Designed to Cross the Blood-Brain Barrier

Volker Schellenberger

Chief Scientific Officer
Amunix

XTEN: A Protein-Based, Biodegradable PEG Alternative with a Controlled Chemical Composition

Peter Daddona

Chief Scientific Officer
Zosano Pharma

Advancing Microneedle Patch Technology To Commercialization

Hanspeter Michel

Senior Principal Scientist
Hoffmann-La Roche Inc.

Peptide Analytical Methods In Drug Discovery And Development

George Barany

Professor
University of Minnesota

Recent Advances in Solid-Phase Peptide Synthesis

David Fry

Senior Research Leader
Hoffmann La-Roche

Drug-Like Inhibitors Of Protein-Protein Interactions: Peptide Mimicry And Fragment Approaches

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.